SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J. K. Lim, J. P. Tate, S. L. Fultz, J. L. Goulet, J. Conigliaro, K. J. Bryant, A. J. Gordon, C. Gibert, D. Rimland, M. Bidwell Goetz, M. B. Klein, D. A. Fiellin, A. C. Justice, V. Lo Re, Relationship Between Alcohol Use Categories and Noninvasive Markers of Advanced Hepatic Fibrosis in HIV-Infected, Chronic Hepatitis C Virus-Infected, and Uninfected Patients, Clinical Infectious Diseases, 2014, 58, 10, 1449

    CrossRef

  2. 2
    Martin-Walter Welker, Wolf Peter Hofmann, Christian Markus Lange, Eva Herrmann, Christoph Sarrazin, Stefan Zeuzem, Bernd Kronenberger, CD81 expression for discrimination between sustained virologic response and relapse in patients with chronic hepatitis C, Scandinavian Journal of Gastroenterology, 2011, 46, 7-8, 973

    CrossRef

  3. 3
    C. Puoti, G. Barbarini, A. Picardi, M. Romano, A. Pellicelli, A. Barlattani, F. Mecenate, R. Guarisco, O. M. Costanza, L. Spilabotti, L. Bellis, M. E. Bonaventura, O. Dell’ Unto, M. G. Elmo, A. M. Nicolini, L. Nosotti, F. Soccorsi, Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study, Journal of Viral Hepatitis, 2011, 18, 6
  4. 4
    Viola Weich, Eva Herrmann, Tje Lin Chung, Christoph Sarrazin, Holger Hinrichsen, Peter Buggisch, Tilman Gerlach, Hartwig Klinker, Ulrich Spengler, Alexandra Bergk, Stefan Zeuzem, Thomas Berg, The determination of GGT is the most reliable predictor of nonresponsiveness to interferon-alpha based therapy in HCV type-1 infection, Journal of Gastroenterology, 2011, 46, 12, 1427

    CrossRef

  5. 5
    P. Deltenre, V. Canva, M. El Nady, C. François, S. Castelain, S. Dharancy, A. Louvet, L. Bocket, M. Lazrek, A. Hollebecque, F. Wartel, J. Henrion, G. Duverlie, P. Mathurin, A 2-log drop in viral load at 1 month is the best predictor of sustained response in HCV patients with normal ALT: a kinetic prospective study, Journal of Viral Hepatitis, 2009, 16, 7
  6. 6
    Tatsuki Ichikawa, Kazuhiko Nakao, Hisamitsu Miyaaki, Susumu Eguchi, Mitsuhisa Takatsuki, Masumi Fujimito, Motohisa Akiyama, Satoshi Miuma, Eisuke Ozawa, Hidetaka Shibata, Shigeyuki Takeshita, Takashi Kanematsu, Katsumi Eguchi, Hepatitis C virus kinetics during the first phase of pegylated interferon-α-2b with ribavirin therapy in patients with living donor liver transplantation, Hepatology Research, 2009, 39, 9
  7. You have free access to this content7
    Lan Lin, Louis Libbrecht, Jannick Verbeeck, Chris Verslype, Tania Roskams, Jos van Pelt, Marc Van Ranst, Johan Fevery, Quantitation of replication of the HCV genome in human livers with end-stage cirrhosis by strand-specific real-time RT-PCR assays: Methods and clinical relevance, Journal of Medical Virology, 2009, 81, 9
  8. 8
    Hiroshi Murayama, Masaki Ikemoto, Yoshihiro Fukuda, Shoji Tsunekawa, Atsuo Nagata, Advantage of serum type-I arginase and ornithine carbamoyltransferase in the evaluation of acute and chronic liver damage induced by thioacetamide in rats, Clinica Chimica Acta, 2007, 375, 1-2, 63

    CrossRef

  9. 9
    Graham S Cooke, Janice Main, Improving the treatment of hepatitis C infection in the UK, Expert Opinion on Pharmacotherapy, 2007, 8, 2, 183

    CrossRef

  10. 10
    J. Crespo, Candidatos al tratamiento. Pacientes con ALT normales, Gastroenterología y Hepatología, 2006, 29, 117

    CrossRef

  11. 11
    H. Hagan, M. H. Latka, J. V. Campbell, E. T. Golub, R. S. Garfein, D. A. Thomas, F. Kapadia, S. A. Strathdee, Eligibility for Treatment of Hepatitis C Virus Infection among Young Injection Drug Users in 3 US Cities, Clinical Infectious Diseases, 2006, 42, 5, 669

    CrossRef

  12. 12
    S. ZEUZEM, A. ALBERTI, W. ROSENBERG, P. MARCELLIN, M. DIAGO, F. NEGRO, D. PRATI, C. PUOTI, S. K. ROBERTS, M. L. SHIFFMAN, Review article: management of patients with chronic hepatitis C virus infection and ‘normal’ alanine aminotransferase activity, Alimentary Pharmacology & Therapeutics, 2006, 24, 8
  13. 13
    Eva Herrmann, Stefan Zeuzem, The kinetics of hepatitis C virus, European Journal of Gastroenterology & Hepatology, 2006, 18, 4, 339

    CrossRef

  14. 14
    Alex Yui Hui, Joseph Jao-Yiu Sung, Advances in chronic viral hepatitis, Current Opinion in Infectious Diseases, 2005, 18, 5, 400

    CrossRef

  15. 15
    Alex Yui Hui, Joseph Jao-Yiu Sung, Advances in chronic viral hepatitis, Current Opinion in Internal Medicine, 2005, 4, 6, 548

    CrossRef

  16. 16
    Geoffrey Dusheiko, Mark Danta, Can Peg-IFN α-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?, Nature Clinical Practice Gastroenterology & Hepatology, 2005, 2, 3, 130

    CrossRef

  17. 17
    Gillian M Keating, Greg L Plosker, Peginterferon ??-2a (40KD) Plus Ribavirin, Drugs, 2005, 65, 4, 521

    CrossRef

  18. 18
    Bernd Kronenberger, Stefan Zeuzem, Reply, Gastroenterology, 2005, 128, 5, 1532

    CrossRef

  19. 19
    Claudio Puoti, Lia Bellis, Roberto Castellacci, Fabrizio Montagnese, Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels, Hepatology, 2005, 41, 3